We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Completes Sale of AbD Serotec to Bio-Rad
News

MorphoSys Completes Sale of AbD Serotec to Bio-Rad

MorphoSys Completes Sale of AbD Serotec to Bio-Rad
News

MorphoSys Completes Sale of AbD Serotec to Bio-Rad

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Completes Sale of AbD Serotec to Bio-Rad"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that the sale of its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, Inc. has been completed.

All assets and liabilities of the AbD Serotec segment of MorphoSys AG as well as all shares of the subsidiaries MorphoSys UK Ltd., MorphoSys AbD GmbH and MorphoSys US, Inc. have been transferred to Bio-Rad.

"We are delighted to have reached the closing of the transaction just a few weeks after the announcement was made. With the divestment of AbD Serotec completed, MorphoSys can devote 100% of its attention to building value in its core therapeutics business," commented Jens Holstein, Chief Financial Officer of MorphoSys AG.

Advertisement